505903400 02/06/2020

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5950117

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ELAN PHARMACEUTICALS, LLC	09/26/2014

RECEIVING PARTY DATA

Name:	NEOTOPE BIOSCIENCES LIMITED	
Street Address:	25-28 NORTH WALL QUAY	
City:	DUBLIN 1	
State/Country:	IRELAND	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	15129676

CORRESPONDENCE DATA

Fax Number: (312)913-0002

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3129130001

Email: docketing@mbhb.com

Correspondent Name: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP

Address Line 1: 300 S. WACKER DRIVE PATRICK GATTARI Address Line 2:

Address Line 4: CHICAGO, ILLINOIS 60606

ATTORNEY DOCKET NUMBER:	15-1132-WO-US	
NAME OF SUBMITTER:	PATRICK GATTARI	
SIGNATURE:	/Patrick Gattari/	
DATE SIGNED:	02/06/2020	

Total Attachments: 3

source=Elan to Neotope Pro1#page1.tif source=Elan to Neotope Pro1#page2.tif source=Elan to Neotope Pro1#page3.tif

> **PATENT REEL: 051741 FRAME: 0618** 505903400

ASSIGNMENT

THIS ASSIGNMENT, by ELAN PHARMACEUTICALS, LLC, a corporation duly organized under and pursuant to the laws of Delaware, and having its principal place of business at 515 Eastern Avenue, Allegan, MI 49010 (hereinafter referred to as "Assignor"), witnesseth:

WHEREAS, Assignor is the owner of and undivided right, title and interest in and to the invention set forth as follows:

Title of Invention: Blood-Brain Barrier Shuttles Containing Antibodies

Recognizing Alpha-Synuclein

US Application No.: 61/977,039

Filing Date: April 8, 2014

WHEREAS, NEOTOPE BIOSCIENCES LIMITED, a private limited company incorporated under the laws of Ireland, and having its registered office at 25-28 North Wall Quay, Dublin 1, Ireland (hereinafter referred to as "Assignee"), pursuant to the Research and Development Agreement dated as of March 23, 2010 (hereinafter referred to as "the R&D Agreement") between Assignor and Assignee, has acquired Assignor's right, title, and interest in and to the above-mentioned application and invention, the right to file applications on said invention, and the right, title and interest in and to any applications, including provisional applications, on said invention for Letters Patent of the United States or other countries, and any applications claiming priority to said applications, and in and to any Letters Patent or Patents of any country, to be obtained therefor and thereon;

NOW, THEREFORE, pursuant to the R&D Agreement, for good and sufficient consideration, the receipt of which is hereby acknowledged, Assignor has assigned, transferred, and set over, and by these presents does assign, transfer, and set over unto Assignee, and Assignee's successors, legal representatives, and assigns, all of Assignor's right, title, and interest in and to the above-mentioned invention and application, the right to file applications on said invention and the right, title and interest in and to any such applications, including provisional applications, and any applications claiming priority from said applications for Letters Patent of the United States or other countries, and any and all Letters Patent or Patents of the United States of America and all foreign countries that have been or may be granted therefor and thereon, and in and to any and all divisions, renewals, substitutions, conversions, continuations, and continuations-in-part of said applications, and reissues, prolongations and extensions of said Letters Patent or Patents, and all rights under the Paris Convention for the Protection of Industrial Property, including the right to claim priority, the same to be held and enjoyed by Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by Assignor had its assignment not been made;

AND Assignor hereby covenants that Assignor has the full right to convey the interest assigned by this Assignment, and Assignor has not executed and will not execute any agreement in conflict with this Assignment;

PATENT REEL: 051741 FRAME: 0619 AND for the same consideration, Assignor hereby covenants and agrees to and with Assignee, its successors, legal representatives, and assigns, that Assignor shall, whenever counsel of Assignee, or the counsel of its successors, legal representatives, and assigns, advises that any proceeding in connection with said invention or said applications for Letters Patent or Patents, or any proceeding in connection with Letters Patent or Patents for said invention in any country, including interference proceedings, is lawful and desirable, or that any application claiming priority to said applications, division, continuation, continuation-in-part, substitution or conversion of any applications for Letters Patent or Patents, or any reissue, prolongation or extension of any Letters Patent or Patents to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said invention, without charge to Assignee, but at the cost and expense of Assignee, its successors, legal representatives, and assigns;

AND Assignor hereby requests the Commissioner of Patents to issue any and all said Letters Patent or Patents of the United States to Assignee as the assignee of said invention and the Letters Patent or Patents issued and to be issued thereon for the sole use and behalf of Assignee, its successors, legal representatives, and assigns.

IN TESTIMONY WHEREOF, a duly authorized representative of Assignor has signed on the date indicated.

ELAN PHARMACEUTICALS, LLC

Date: Septender 26, 2014

Dy.

Printed Name: Andrew M. Solomon Title: Chief Intellectual Property Officer

September 26, 2014 in Allegan, MI

Notery Public, State of Michigan County of Allegan

My Commission Expires 07-24-2018
Acting in the County of

EXECUTE IN THE PRESENCE OF A NOTARY

LEGAL02/35027160v1

IN TESTIMONY WHEREOF, a duly authorized representative of Assignee has signed on the date indicated.

NEOTOPE BIOSCIENCES LIMITED

Date: Ochobes 2

WHEREOF an act being required of me GEORGINA DRUM, a Notary Public In The City and County of Dublin, Ireland I have IN WITNESS set by hand and Affixed my official Seal of Office

168 PEMBROKE ROAD. BALLSBRIDGE, DUBLIN 4.
Motary Public for the County and City of Dublin Ireland.
Commissioned for Life

EXECUTE IN THE PRESENCE OF A NOTARY

LEGAL02/35027160v1

RECORDED: 02/06/2020

PATENT REEL: 051741 FRAME: 0621